Valuation: Verastem, Inc.

Market Cap 395M 346M 318M 296M 562M 37.65B 570M 3.81B 1.48B 18.51B 1.48B 1.45B 63.77B P/E 2026 *
-2.85x
P/E 2027 * -4.03x
Enterprise Value 230M 201M 185M 173M 327M 21.94B 332M 2.22B 864M 10.78B 865M 846M 37.16B EV / Sales 2026 *
2.25x
EV / Sales 2027 * 1.04x
Free-Float
99.07%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Verastem, Inc.

1 day+9.76%
1 week+19.05%
Current month+17.80%
1 month+21.29%
3 months-20.07%
6 months-34.50%
Current year-41.71%
1 week 3.74
Extreme 3.745
4.57
1 month 3.43
Extreme 3.43
4.57
Current year 3.43
Extreme 3.43
8.88
1 year 3.43
Extreme 3.43
11.24
3 years 2.1
Extreme 2.1
14.22
5 years 2.1
Extreme 2.1
47.16
10 years 2.1
Extreme 2.1
124.2
Manager TitleAgeSince
Chief Executive Officer 65 01/08/2023
Director of Finance/CFO 39 31/10/2022
Chief Tech/Sci/R&D Officer - 18/04/2024
Director TitleAgeSince
Chairman 62 -
Director/Board Member 65 01/08/2023
Director/Board Member 69 03/05/2017
Date Insider Type Main position Quantity % Market Cap.
22/06Sell

Chief Financial Officer

-4,089 0.0066%
22/06Sell

Chief Executive Officer

-20,871 0.0339%
21/05Free

Director

36,000 0.0410%
Change 5-day change 1-year change 3-year change Capi.($)
+9.76%+19.05%-6.25%-42.89% 395M
+0.68%+5.92%+77.86%+136.97% 59.1B
+2.32%+5.03%+75.26%+92.31% 55.19B
+3.86%+6.93%-11.32%-10.57% 24.67B
+4.30%+7.95%+14.11%+440.44% 24.19B
+0.69%+7.43%+51.30%-0.79% 19.69B
-0.29%+9.78%+43.90%-29.12% 17.56B
0.00%+20.78%+186.15%+347.42% 16.22B
+4.41%+19.38%+47.56% - 14.84B
+3.50%+1.97%+21.02%+193.33% 14.04B
Average +2.92%+10.75%+49.96%+125.23% 24.59B
Weighted average by Cap. +2.02%+6.51%+59.44%+135.85%

Financials

2026 *2027 *
Net sales 102M 89.42M 82.18M 76.6M 145M 9.74B 147M 987M 384M 4.79B 384M 376M 16.5B 179M 156M 144M 134M 254M 17.02B 258M 1.72B 670M 8.37B 671M 657M 28.83B
Net income -166M -145M -134M -124M -236M -15.82B -240M -1.6B -623M -7.78B -624M -610M -26.81B -142M -124M -114M -106M -201M -13.48B -204M -1.37B -531M -6.63B -531M -520M -22.83B
Net Debt -165M -144M -133M -124M -234M -15.71B -238M -1.59B -619M -7.72B -619M -606M -26.61B -210M -183M -168M -157M -298M -19.96B -302M -2.02B -786M -9.81B -787M -770M -33.8B
Logo Verastem, Inc.
Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.
Employees
102
Date Price Change Volume
02/07/26 USD 4.500 +9.76% 2,967,738
01/07/26 USD 4.100 +7.33% 2,186,504
30/06/26 USD 3.820 0.00% 3,445,491
29/06/26 USD 3.820 +1.06% 2,684,221
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
4.500USD
Average target price
15.12USD
Spread / Average Target
+236.11%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VSTM Stock